The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Research Report 2024
Synopsis
The global Severe Acute Respiratory Syndrome (SARS) Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Severe Acute Respiratory Syndrome (SARS) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Severe Acute Respiratory Syndrome (SARS) Therapeutics.
Report Scope
The Severe Acute Respiratory Syndrome (SARS) Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Severe Acute Respiratory Syndrome (SARS) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Severe Acute Respiratory Syndrome (SARS) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
CEL-SCI Corporation
GeneCure LLC
Humabs BioMed SA
Inovio Pharmaceuticals, Inc.
Nanotherapeutics, Inc.
Novavax, Inc.
Phelix Therapeutics, LLC
Protein Sciences Corporation
Segment by Type
CEL-1000
D-3252
FDX-000
INO-4500
LCA-60
Others
Segment by Application
Hospital
Clinic
Research Center
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Severe Acute Respiratory Syndrome (SARS) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Severe Acute Respiratory Syndrome (SARS) Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Severe Acute Respiratory Syndrome (SARS) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Severe Acute Respiratory Syndrome (SARS) Therapeutics.
Report Scope
The Severe Acute Respiratory Syndrome (SARS) Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Severe Acute Respiratory Syndrome (SARS) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Severe Acute Respiratory Syndrome (SARS) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
CEL-SCI Corporation
GeneCure LLC
Humabs BioMed SA
Inovio Pharmaceuticals, Inc.
Nanotherapeutics, Inc.
Novavax, Inc.
Phelix Therapeutics, LLC
Protein Sciences Corporation
Segment by Type
CEL-1000
D-3252
FDX-000
INO-4500
LCA-60
Others
Segment by Application
Hospital
Clinic
Research Center
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Severe Acute Respiratory Syndrome (SARS) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 CEL-1000
1.2.3 D-3252
1.2.4 FDX-000
1.2.5 INO-4500
1.2.6 LCA-60
1.2.7 Others
1.3 Market by Application
1.3.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Research Center
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Perspective (2019-2030)
2.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Growth Trends by Region
2.2.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Dynamics
2.3.1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Trends
2.3.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Drivers
2.3.3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Challenges
2.3.4 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Severe Acute Respiratory Syndrome (SARS) Therapeutics Players by Revenue
3.1.1 Global Top Severe Acute Respiratory Syndrome (SARS) Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue
3.4 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Concentration Ratio
3.4.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue in 2023
3.5 Severe Acute Respiratory Syndrome (SARS) Therapeutics Key Players Head office and Area Served
3.6 Key Players Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Solution and Service
3.7 Date of Enter into Severe Acute Respiratory Syndrome (SARS) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Severe Acute Respiratory Syndrome (SARS) Therapeutics Breakdown Data by Type
4.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Forecasted Market Size by Type (2025-2030)
5 Severe Acute Respiratory Syndrome (SARS) Therapeutics Breakdown Data by Application
5.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2019-2030)
6.2 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2019-2024)
6.4 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2019-2030)
7.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2019-2024)
7.4 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2019-2030)
9.2 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 CEL-SCI Corporation
11.1.1 CEL-SCI Corporation Company Detail
11.1.2 CEL-SCI Corporation Business Overview
11.1.3 CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Introduction
11.1.4 CEL-SCI Corporation Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2019-2024)
11.1.5 CEL-SCI Corporation Recent Development
11.2 GeneCure LLC
11.2.1 GeneCure LLC Company Detail
11.2.2 GeneCure LLC Business Overview
11.2.3 GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Introduction
11.2.4 GeneCure LLC Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2019-2024)
11.2.5 GeneCure LLC Recent Development
11.3 Humabs BioMed SA
11.3.1 Humabs BioMed SA Company Detail
11.3.2 Humabs BioMed SA Business Overview
11.3.3 Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Introduction
11.3.4 Humabs BioMed SA Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2019-2024)
11.3.5 Humabs BioMed SA Recent Development
11.4 Inovio Pharmaceuticals, Inc.
11.4.1 Inovio Pharmaceuticals, Inc. Company Detail
11.4.2 Inovio Pharmaceuticals, Inc. Business Overview
11.4.3 Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Introduction
11.4.4 Inovio Pharmaceuticals, Inc. Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2019-2024)
11.4.5 Inovio Pharmaceuticals, Inc. Recent Development
11.5 Nanotherapeutics, Inc.
11.5.1 Nanotherapeutics, Inc. Company Detail
11.5.2 Nanotherapeutics, Inc. Business Overview
11.5.3 Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Introduction
11.5.4 Nanotherapeutics, Inc. Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2019-2024)
11.5.5 Nanotherapeutics, Inc. Recent Development
11.6 Novavax, Inc.
11.6.1 Novavax, Inc. Company Detail
11.6.2 Novavax, Inc. Business Overview
11.6.3 Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Introduction
11.6.4 Novavax, Inc. Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2019-2024)
11.6.5 Novavax, Inc. Recent Development
11.7 Phelix Therapeutics, LLC
11.7.1 Phelix Therapeutics, LLC Company Detail
11.7.2 Phelix Therapeutics, LLC Business Overview
11.7.3 Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Introduction
11.7.4 Phelix Therapeutics, LLC Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2019-2024)
11.7.5 Phelix Therapeutics, LLC Recent Development
11.8 Protein Sciences Corporation
11.8.1 Protein Sciences Corporation Company Detail
11.8.2 Protein Sciences Corporation Business Overview
11.8.3 Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Introduction
11.8.4 Protein Sciences Corporation Revenue in Severe Acute Respiratory Syndrome (SARS) Therapeutics Business (2019-2024)
11.8.5 Protein Sciences Corporation Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
